Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Pharmacoeconomic Analysis of Ideal Vs. Actual Body Weight-Based Treatment for Adult Persons with Hemophilia Α

Ming Y. Lim, MBBChir,MA, Jeffrey A. Gilreath, PharmD, Paul F. Bray, MD, George M. Rodgers, MD PhD

Blood (2019) 134 (Supplement_1): 4684.

https://doi.org/10.1182/blood-2019-121679

Published: 2019

Journal Articles

Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment

Renato Torrescasana Centrone, Marcelo Bellesso, MD, Rodrigo Santucci Silva, MD, Eliseo J. Sekiya, MD, Milton A. F. Aranha, MD, Isabel Bonafe, Daniela Ferreira Dias, MD, Adelson Alves, MD

Blood (2019) 134 (Supplement_1): 5847.

https://doi.org/10.1182/blood-2019-128629

Published: 2019

Journal Articles

Lenalidomide As Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation: A Pharmacoeconomic Assessment in the Netherlands

Carin A. Uyl-de Groot, Rachel Ramsden, Janneke Boersma, Sonja Zweegman, MD PhD, Sujith Dhanasiri

Blood (2018) 132 (Supplement 1): 3555.

https://doi.org/10.1182/blood-2018-99-112826

Published: 2018

Journal Articles

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective

S. Vincent Rajkumar, Jean Luc Harousseau

Blood (2016) 128 (24): 2757–2764.

https://doi.org/10.1182/blood-2016-09-692947

Published: 2016

Journal Articles

Serum Free Light Chain Assays in the Risk Stratification of Monoclonal Gammopathy of Undetermined Significance: Results from a Pharmacoeconomic Evaluation

Guy Pratt, MDFRCP FRCPath, Holly Cranmer, BSc, Christine Almond, MSC, MMath, Stephen Harding, PhD, Dale John Powner, PhD, Richard Geir Hughes, DPhil, Mark Cook, PhD MBChb

Blood (2015) 126 (23): 3258.

https://doi.org/10.1182/blood.V126.23.3258.3258

Published: 2015

Journal Articles

Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation

Steve Schey, Sujith Dhanasiri, Dawn Lee, Lars Sternas, MD, Xin Yu, Mohamed H. Zaki, MD, Jamie Elvidge, Michael O'Dwyer

Blood (2014) 124 (21): 2649.

https://doi.org/10.1182/blood.V124.21.2649.2649

Published: 2014

Journal Articles

Serum Free Light Chain Assays in the Early Detection of Cast Nephropathy in Patients Presenting with Unexplained Acute Kidney Injury (AKI): Results from a Pharmacoeconomic Evaluation

Mark Cook, PhD FRCPath, Paul Cockwell, Christine Almond, Holly Cranmer, Stephen Harding, MDPhD, Richard Hughes, Chris Knight, Alexander Hirst

Blood (2014) 124 (21): 2612.

https://doi.org/10.1182/blood.V124.21.2612.2612

Published: 2014

Journal Articles

Pharmacoeconomic Implications of Lenalidomide Maintenance Therapy in Multiple Myeloma and the Impact On Survival

Miriam Yunhee Kim, MD, Richard Sposto, PhD, Asher Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2012) 120 (21): 601.

https://doi.org/10.1182/blood.V120.21.601.601

Published: 2012

Journal Articles

Pharmacoeconomic Impact of Upfront Use Plerixafor for Autologous Stem Cell Mobilization in Multiple Myeloma Patients

Luis Isola, MD, Karen M Banoff, RN, MPA, BS, Sara S Kim, BS, Pharm.D., BCOP

Blood (2011) 118 (21): 2075.

https://doi.org/10.1182/blood.V118.21.2075.2075

Published: 2011

Journal Articles

Pharmacoeconomics of Stem Cell Mobilization Using Cyclophosphamide and G-Csf.

Madan Jagasia, MD, MS, Heidi Chen, PhD, Sheri Dixon, Jodene Hume-Rowland, Bipin N. Savani, MD, Anne T. Neff, MD, Kimberely Moyers, Wichai Chinratanalab, MD, Friedrich Schuening, MD

Blood (2009) 114 (22): 4526.

https://doi.org/10.1182/blood.V114.22.4526.4526

Published: 2009

Journal Articles

Pharmacoeconomic Evaluation of Hypomethylating Agents Used for the Treatment of MDS

Bruce Feinberg, James Gilmore, Sally Haislip, Carlos M. Franco, MD, Tom Gondesen, Mansoor N. Saleh, MD

Blood (2008) 112 (11): 2380.

https://doi.org/10.1182/blood.V112.11.2380.2380

Published: 2008

NARROW

Pharmacoeconomic Analysis of Ideal Vs. Actual Body Weight-Based Treatment for Adult Persons with Hemophilia Α

Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment

Lenalidomide As Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation: A Pharmacoeconomic Assessment in the Netherlands

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective

Serum Free Light Chain Assays in the Risk Stratification of Monoclonal Gammopathy of Undetermined Significance: Results from a Pharmacoeconomic Evaluation

Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation

Serum Free Light Chain Assays in the Early Detection of Cast Nephropathy in Patients Presenting with Unexplained Acute Kidney Injury (AKI): Results from a Pharmacoeconomic Evaluation

Pharmacoeconomic Implications of Lenalidomide Maintenance Therapy in Multiple Myeloma and the Impact On Survival

Pharmacoeconomic Impact of Upfront Use Plerixafor for Autologous Stem Cell Mobilization in Multiple Myeloma Patients

Pharmacoeconomics of Stem Cell Mobilization Using Cyclophosphamide and G-Csf.

Pharmacoeconomic Evaluation of Hypomethylating Agents Used for the Treatment of MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only